Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (1)
P 2 (2)

Trial Status

Withdrawn2
Unknown2
Not Yet Recruiting1
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT04420975Phase 1Active Not Recruiting

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT05974410Unknown

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

NCT06526897Not ApplicableNot Yet Recruiting

Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

NCT03874455Unknown

Tazemetostat Expanded Access Program for Adults With Solid Tumors

NCT05116800Phase 2Withdrawn

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

NCT04906876Phase 2Withdrawn

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Showing all 6 trials

Research Network

Activity Timeline